MK-431 (Merck).

Research output: Contribution to journalJournal articleResearchpeer-review

Merck & Co is developing MK-431, the lead from a series of dipeptidyl peptidase IV inhibitors that enhance endogenous glucagon-like peptide-1 levels, for the potential treatment of type 2 diabetes. Phase III studies were initiated in the second quarter of 2004.
Original languageEnglish
JournalCurrent Opinion in Investigational Drugs
Issue number4
Pages (from-to)419-26
Number of pages7
Publication statusPublished - 2005

Bibliographical note

Keywords: Adenosine Deaminase; Animals; Antigens, CD26; Clinical Trials as Topic; Drug Industry; Glycoproteins; Humans; Hypoglycemic Agents; Protease Inhibitors; Pyrazines; Triazoles

ID: 8417240